Tatva Chintan Pharma Chem
Tatva Chintan Pharma Chem Share Price Chart
Tatva Chintan Pharma Chem last traded at ₹1,870.00 (2026-10-13). Over the past month the stock moved +12.2%, three months the stock moved +61.5%, year the stock moved +69.2%. Its closing range over 52 weeks is ₹1,090.20 – ₹1,999.00, with the latest close 6.5% below the high.
Closing prices up to 2026-10-13.
About Tatva Chintan Pharma Chem
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
Product Portfolio: Tatva Chintan has a portfolio of 214 products divided into 4 categories: [1] a) Pharmaceuticals & Agrochemicals Intermediates and other Specialty Chemicals (PASC):[2][3] PASC is used to produce intermediates, catalysts, and solvents for industries like pharmaceuticals, agrochemicals, and disinfectants. The company specializes in manufacturing Glymes, a solvent essential for API production. It is India's largest Glyme producer and ranks 3rd globally. [4] [5] [6] b) Structure Directing Agents (SDA): The company manufactures SDAs, a crucial raw material for producing high-precision zeolites, which find industrial uses as catalysts and adsorbents across automotive, petrochemicals and other industries. It is the 2nd largest manufacturer of SDAs for Zeolites globally and the largest commercial supplier in India.[7] [6] c) Phase Transfer Catalyst (PTC): The company is India’s leading producer of PTC. PTCs play a key role in heterogeneous multiphase systems by aiding reactant migration. They are utilized in pharmaceutical APIs, agrochemicals, flavors and fragrances, and environmental control processes.[7][6] d) Electrolyte Salts & Others: Electrolyte Salts are used to manufacture supercapacitor batteries. The company is India’s largest producer of electrolyte salts and solutions for supercapacitor batteries. It also manufactures Brominated Flame Retardants, essential in the construction, electronics, and automotive industries. [8]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Tatva Chintan Pharma Chem reported sales of ₹167.00 crore (+42.7%) and net profit of ₹16.00 crore (+128.6%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 167.00 | 32.00 | 19.00 | 16.00 | 6.83 |
| Mar 2026 | 134.00 | 28.00 | 21.00 | 10.00 | 4.41 |
| Dec 2025 | 131.00 | 25.00 | 19.00 | 15.00 | 6.49 |
| Sep 2025 | 124.00 | 22.00 | 18.00 | 10.00 | 4.24 |
| Jun 2025 | 117.00 | 17.00 | 15.00 | 7.00 | 2.84 |
| Mar 2025 | 108.00 | 9.00 | 8.00 | 1.00 | 0.44 |
| Dec 2024 | 86.00 | 7.00 | 8.00 | 0.00 | 0.06 |
| Sep 2024 | 83.00 | 6.00 | 7.00 | -1.00 | -0.28 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -14.4% | +2.4% | +10.2% | +11.4% | +49.4% | +52.3% | +24.1% | +42.7% |
| Operating profit growth | -70.0% | -36.4% | -43.8% | +30.8% | +266.7% | +257.1% | +211.1% | +88.2% |
| Net profit growth | -112.5% | -100.0% | -90.0% | +40.0% | – | – | +900.0% | +128.6% |
| EPS growth | -108.4% | -95.9% | -89.3% | +27.4% | – | +10716.7% | +902.3% | +140.5% |
| OPM % | 7.0% | 8.0% | 8.0% | 15.0% | 18.0% | 19.0% | 21.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Tatva Chintan Pharma Chem reported sales of ₹506.00 crore (+32.1%) and net profit of ₹42.00 crore (+600.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 506.00 | 93.00 | 18.00 | 42.00 | 17.98 |
| Mar 2025 | 383.00 | 34.00 | 9.00 | 6.00 | 2.44 |
| Mar 2024 | 394.00 | 69.00 | 17.00 | 30.00 | 12.97 |
| Mar 2023 | 424.00 | 61.00 | 14.00 | 45.00 | 20.52 |
| Mar 2022 | 434.00 | 109.00 | 25.00 | 96.00 | 43.25 |
| Mar 2021 | 300.00 | 67.00 | 22.00 | 52.00 | 26.02 |
| Mar 2020 | 263.00 | 55.00 | 21.00 | 38.00 | 47.03 |
| Mar 2019 | 206.00 | 34.00 | 17.00 | 21.00 | 25.56 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +51.5% | +27.7% | +14.1% | +44.7% | -2.3% | -7.1% | -2.8% | +32.1% |
| Operating profit growth | +47.8% | +61.8% | +21.8% | +62.7% | -44.0% | +13.1% | -50.7% | +173.5% |
| Net profit growth | +75.0% | +81.0% | +36.8% | +84.6% | -53.1% | -33.3% | -80.0% | +600.0% |
| EPS growth | +67.1% | +84.0% | -44.7% | +66.2% | -52.6% | -36.8% | -81.2% | +636.9% |
| OPM % | 17.0% | 21.0% | 22.0% | 25.0% | 14.0% | 17.0% | 9.0% | 18.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Tatva Chintan Pharma Chem.
Get Free AI Stock Analysis FREE →Latest News
-
Tatva Chintan Pharma Chem Ltd leads gainers in 'B' group - Business Standard
-
Mukul Agrawal portfolio stock Tatva Chintan Pharma zooms 20%; here's why - Business Standard
-
Tatva Chintan Pharma Chem shares surge 16% after Q1 profit more than doubles - Moneycontrol.com
-
Tatva Chintan Pharma rallies after Q1 PAT jumps more than two-fold - Business Standard
-
Tatva Chintan Pharma Chem Q4 & FY26 Results: Net Profit Surges, EBITDA Margin Expands - scanx.trade
-
Tatva Chintan Standalone March 2026 Net Sales at Rs 132.67 crore, up 23.24% Y-o-Y - Moneycontrol.com
-
Tatva Chintan Standalone March 2026 Net Sales at Rs 132.67 crore, up 23.24% Y-o-Y - Moneycontrol.com
-
Tatva Chintan Pharma Chem Publishes Q4 & FY26 Financial Results Extract in Newspapers - scanx.trade
-
Tatva Chintan Pharma reports Profit after tax of Rs 90.23 Mln, in the March 2026 quarter
-
Tatva Chintan Pharma Chem standalone net profit rises 720.00% in the March 2026 quarter - Business Standard
Frequently Asked Questions
What is the share price of Tatva Chintan Pharma Chem today?
Tatva Chintan Pharma Chem shares were last quoted at ₹1,870.00 (+3.6% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Tatva Chintan Pharma Chem?
Tatva Chintan Pharma Chem has a price-to-earnings (P/E) ratio of 81.72 and a price-to-book (P/B) ratio of 5.27. The industry P/E is 60.32.
What is the 52-week high and low of Tatva Chintan Pharma Chem?
The 52-week high of Tatva Chintan Pharma Chem is ₹1,838.85 and the 52-week low is ₹988.00.
What is the market cap of Tatva Chintan Pharma Chem?
The market capitalisation of Tatva Chintan Pharma Chem is about ₹4,199.81 crore.
How did Tatva Chintan Pharma Chem perform in its latest quarterly results?
In the latest quarter (Jun 2026), Tatva Chintan Pharma Chem reported sales of ₹167.00 crore (+42.7%) and net profit of ₹16.00 crore (+128.6%), compared with the same quarter last year.
Is Tatva Chintan Pharma Chem a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Tatva Chintan Pharma Chem has a 3-year ROE of 4.00%, 3-year profit growth of -5.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Tatva Chintan Pharma Chem?
Promoters hold about 72.02% of Tatva Chintan Pharma Chem.
Which sector does Tatva Chintan Pharma Chem belong to?
Tatva Chintan Pharma Chem belongs to the Speciality Chemicals sector.